1. Achermann JC, Jameson JL. Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Mol Endocrinol 1999; 13(6):812-818.
2. Dattani MT, Martinez-Barbera JP, Thomas PQ et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998; 19(2):125-133.
3. Aarskog D, Eiken HG, Bjerknes R, Myking OL. Pituitary dwarfism in the R271W Pit-1 gene mutation. Eur J Pediatr 1997; 156(11):829-834.
4. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992; 257(5073):1115-1118.
5. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84(12):4362-4370.
6. Fofanova O, Takamura N, Kinoshita E et al. Compound heterozygous deletion of the PROP-1 gene in children with combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998; 83(7):2601-2604.
7. Deladoey J, Fluck C, Buyukgebiz A et al. "Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1999; 84(5):1645-1650.
8. Bick D, Franco B, Sherins RJ et al. Brief report: intragenic deletion of the KALIG-1 gene in Kallmann's syndrome. N Engl J Med 1992; 326(26):1752-1755.
9. Burris TP, Guo W, McCabe ER. The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Recent Prog Horm Res 1996; 51:241-259.
10. Fantes J, Ragge NK, Lynch SA et al. Mutations in SOX2 cause anophthalmia. Nat Genet 2003; 33(4):461-463.
11. Kelberman D, de Castro SC, Huang S et al. SOX2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. J Clin Endocrinol Metab 2008; 93(5):1865-1873.
12. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996; 78(3):502-510.
13. Katznelson L, Alexander JM, Klibanski A. Clinical review 45: Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993; 76(5):1089-1094.
14. Adams CB. The management of pituitary tumours and post-operative visual deterioration. Acta Neurochir (Wien ) 1988; 94(3-4):103-116.
15. DeVile CJ, Grant DB, Hayward RD, Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child 1996; 75(2):108-114.
16. Adamson TE, Wiestler OD, Kleihues P, Yasargil MG. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg 1990; 73(1):12-17.
17. Ross DA, Norman D, Wilson CB. Radiologic characteristics and results of surgical management of Rathke's cysts in 43 patients. Neurosurgery 1992; 30(2):173-178.
18. Takeuchi J, Handa H, Nagata I. Suprasellar germinoma. J Neurosurg 1978; 49(1):41-48.
19. Ho DM, Liu HC. Primary intracranial germ cell tumor. Pathologic study of 51 patients. Cancer 1992; 70(6):1577-1584.
20. Janmohamed S, Grossman AB, Metcalfe K et al. Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemoradiotherapy regimen. Clin Endocrinol (Oxf) 2002; 57(4):487-500.
21. Max MB, Deck MD, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology 1981; 31(8):998-1002.
22. Bills DC, Meyer FB, Laws ER, Jr. et al. A retrospective analysis of pituitary apoplexy. Neurosurgery 1993; 33(4):602-608.
23. Wakai S, Fukushima T, Teramoto A, Sano K. Pituitary apoplexy: its incidence and clinical significance. J Neurosurg 1981; 55(2):187-193.
24. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 1999; 51(2):181-188.
25. Barkan AL. Pituitary atrophy in patients with Sheehan's syndrome. Am J Med Sci 1989; 298(1):38-40.
26. Jenkins PJ, Chew SL, Lowe DG et al. Lymphocytic hypophysitis: unusual features of a rare disorder. Clin Endocrinol (Oxf) 1995; 42(5):529-534.
27. Cheung CC, Ezzat S, Smyth HS, Asa SL. The spectrum and significance of primary hypophysitis. J Clin Endocrinol Metab 2001; 86(3):1048-1053.
28. Asa SL, Bilbao JM, Kovacs K, Josse RG, Kreines K. Lymphocytic hypophysitis of pregnancy resulting in hypopituitarism: a distinct clinicopathologic entity. Ann Intern Med 1981; 95(2):166-171.
29. Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80(8):2302-2311.
30. Ji JD, Lee SY, Choi SJ, Lee YH, Song GG. Lymphocytic hypophysitis in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18(1):78-80.
31. Chapelon C, Ziza JM, Piette JC et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69(5):261-276.
32. Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand 1986; 73(3):283-290.
33. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42(9):909-917.
34. Willman CL, Busque L, Griffith BB et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 1994; 331(3):154-160.
35. Kaltsas GA, Powles TB, Evanson J et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85(4):1370-1376.
36. Basaria S, Ayala AR, Guerin C, Dobs AS. A rare pituitary lesion. J Endocrinol Invest 2000; 23(3):189-192.
37. Ferreiro J, Vinters HV. Pathology of the pituitary gland in patients with the acquired immune deficiency syndrome (AIDS). Pathology 1988; 20(3):211-215.
38. Milligan SA, Katz MS, Craven PC, Strandberg DA, Russell IJ, Becker RA. Toxoplasmosis presenting as panhypopituitarism in a patient with the acquired immune deficiency syndrome. Am J Med 1984; 77(4):760-764.
39. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989; 70(262):145-160.
40. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007; 298(12):1429-1438.
41. Agha A, Phillips J, O'Kelly P, Tormey W, Thompson CJ. The natural history of post-traumatic hypopituitarism: implications for assessment and treatment. Am J Med 2005; 118(12):1416.
42. de BH, Blok GJ, van d, V. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16(1):63-86.
43. Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83(2):382-395.
44. Christ ER, Carroll PV, Russell-Jones DL, Sonksen PH. The consequences of growth hormone deficiency in adulthood, and the effects of growth hormone replacement. Schweiz Med Wochenschr 1997; 127(35):1440-1449.
45. Bulow B, Hagmar L, Eskilsson J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 2000; 85(2):574-584.
46. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997; 137(3):240-245.
47. Maghnie M, Cosi G, Genovese E et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343(14):998-1007.
48. Trainer PJ, Besser GM. The Bart's Protocols. 1995. Churchill Livingstone.
Ref Type: Generic
49. Hurel SJ, Thompson CJ, Watson MJ, Harris MM, Baylis PH, Kendall-Taylor P. The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1996; 44(2):141-146.
50. Parvord SR, Girach A, Price DE, Absalom SR, Falconer-Smith J, Hewlett TA. A retrospective audit of the combined pituitary function test, using the insulin stress test, TRH and GnRH in a district laboratory. Clin Endocrinol (Oxf) 36[2], 135-139. 1992.
Ref Type: Generic
51. Jones SL, Trainer PJ, Perry L, Wass JA, Bessser GM, Grossman A. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year. Clin Endocrinol (Oxf) 1994; 41(1):123-128.
52. Littley MD, Gibson S, White A, Shalet SM. Comparison of the ACTH and cortisol responses to provocative testing with glucagon and insulin hypoglycaemia in normal subjects. Clin Endocrinol (Oxf) 1989; 31(5):527-533.
53. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KK. Diagnosis of growth-hormone deficiency in adults. Lancet 1994; 343(8905):1064-1068.
54. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000; 85(11):3990-3993.
55. Ghigo E, Bellone J, Aimaretti G et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab 1996; 81(9):3323-3327.
56. Valetto MR, Bellone J, Baffoni C et al. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996; 135(5):568-572.
57. Maghnie M, Cavigioli F, Tinelli C et al. GHRH plus arginine in the diagnosis of acquired GH deficiency of childhood-onset. J Clin Endocrinol Metab 2002; 87(6):2740-2744.
58. Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med 1988; 81(9):514-516.
59. Peacey SR, Guo CY, Robinson AM et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46(3):255-261.
60. Swords FM, Drake WM, Carroll PV, Monson JP. Hormonal therapy for hypopituitarism. Encyclopaedia of Endocrine Disease 2, 662-671. 2004.
Ref Type: Generic
61. Newell-Price J, Whiteman M, Rostami-Hodjegan A et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008; 68(1):130-135.
62. Debono M, Ghobadi C, Rostami-Hodjegan A et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009; 94(5):1548-1554.
63. Johannsson G, Burman P, Wiren L et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002; 87(5):2046-2052.
64. Brooke AM, Kalingag LA, Miraki-Moud F et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006; 91(10):3773-3779.
65. Brooke AM, Kalingag LA, Miraki-Moud F et al. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement. Clin Endocrinol (Oxf) 2006; 65(5):673-680.
66. Agha A, Walker D, Perry L et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) 2007; 66(1):72-77.
67. Martins MR, Doin FC, Komatsu WR, Barros-Neto TL, Moises VA, Abucham J. Growth hormone replacement improves thyroxine biological effects: implications for management of central hypothyroidism. J Clin Endocrinol Metab 2007; 92(11):4144-4153.
68. Losa M, Scavini M, Gatti E et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 2008; 18(12):1249-1254.
69. franklyn JA. Diagnosis and treatment of thyrotrophin deficiency. The diagnosis and treatment of pituitary insufficiency . 1997. BioScientificfica.
Ref Type: Generic
70. Bhasin S, Storer TW, Berman N et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82(2):407-413.
71. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005; 6(10):1751-1759.
72. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71(1):216-222.
73. Arver S, Dobs AS, Meikle AW et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997; 47(6):727-737.
74. Swerdloff RS, Wang C, Cunningham G et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85(12):4500-4510.
75. Korbonits M, Slawik M, Cullen D et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004; 89(5):2039-2043.
76. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91(6):1995-2010.
77. Odeh M, Oliven A. Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. J Clin Pharmacol 2001; 41(5):582-584.